• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Creatd Files Form S-1, Reports First Quarter 2026 Results and Updates Annual Meeting Schedule

    6/23/26 9:15:00 AM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $CRTD alert in real time by email
    • First Quarter Results Filed: Creatd filed its Quarterly Report for the period ended March 31, 2026, reviewed by the Company's PCAOB-registered independent auditors, highlighting significant balance sheet developments following the disposition of Flyte.
    • SEC Registration Progress: The Company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission as part of its initiative to re-establish SEC reporting status.
    • Annual Meeting Update: Creatd has revised the record date for its annual shareholder meeting to Friday, June 26, 2026, and the meeting date to Monday, August 3, 2026. Shareholders of record as of June 26, 2026, will be entitled to vote at the meeting.
    • Shareholder Alignment: Founder and CEO Jeremy Frommer has exchanged certain warrants and Preferred Stock holdings into common stock, simplifying the Company's capital structure and support its long-term objective of pursuing an uplisting to a national securities exchange.

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) today announced the filing of its Quarterly Report for the period ended March 31, 2026, reviewed by the Company's PCAOB-registered independent auditors, as well as the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission. The Company also announced revisions to the record date and meeting date for its upcoming annual shareholder meeting and provided an update regarding recent capital structure simplification efforts.

    "The first quarter marked an important milestone in Creatd's continued evolution," said Jeremy Frommer, Chairman and Chief Executive Officer of Creatd. "The filing of our quarterly financial statements and Form S-1 registration statement reflects our commitment to transparency and disciplined execution. At the same time, the simplification of our capital structure further aligns management with shareholders as we continue building long-term value."

    For the quarter ended March 31, 2026, Creatd reported revenue of approximately $204,000 and gross profit of approximately $202,000. The Company ended the quarter with approximately $250,000 in cash and cash equivalents and total current assets of approximately $10.9 million.

    The Company's balance sheet reflects significant consideration received from the previously announced disposition of Flyte to Catheter Precision, Inc. (NYSE:VTAK), including a preferred stock receivable valued at approximately $5.6 million and a promissory note receivable valued at approximately $4.8 million. Together, these assets contributed to total assets of approximately $12.1 million as of March 31, 2026.

    In addition, the Company continues to maintain a significant equity position in VTAK, aligning its interests with the long-term success of the business. VTAK is a significant client of Creatd’s. Creatd is actively involved as a strategic advisor, providing ongoing consultation related to technology development, product innovation, and growth initiatives as VTAK advances the Flyte aviation platform and related technologies.

    During the quarter, Creatd generated approximately $981,000 of cash from investing activities and continued to streamline its operating structure following a series of strategic transactions completed over the past year, including the acquisition of a minority interest in PCG Advisory Group. The Company continues to expand its portfolio with the recent control positions acquired in both Vocal, Inc. and OG Collection, Inc.

    Reported results for the quarter include several significant non-cash accounting charges, including approximately $11.3 million of stock-based compensation expense and approximately $1.2 million of debt discount accretion. These items materially impacted reported net income but did not affect the Company's cash position and enterprise value.

    The Company has publicly filed a registration statement on Form S-1 with the Securities and Exchange Commission as part of its effort to re-establish SEC reporting status. Creatd believes that returning to SEC reporting will enhance transparency, improve accessibility for investors, and set the stage for the Company’s plan to uplist to a national exchange.

    As part of its ongoing corporate governance initiatives, Creatd has revised the record date and meeting date for its 2026 Annual Meeting of Shareholders. Shareholders of record as of Friday, June 26, 2026, will be entitled to notice of and to vote at the meeting, which will now be held on Monday, August 3, 2026. The revised schedule is intended to provide shareholders with additional time to review the Company's recent filings and corporate developments in advance of the meeting.

    Creatd will host an investor call on July 7, 2026, to provide shareholders and interested parties with updates regarding the Company's recent developments, strategic initiatives, and corporate progress. Additional details regarding the investor call, including participation information, will be announced prior to the event.

    Jeremy Frommer has completed the conversion of certain warrant and preferred stock holdings into common stock. This transaction is intended to simplify the Company's capital structure by reducing the number of outstanding security classes and creating a more streamlined equity profile.

    As part of the Company's uplisting strategy, all preferred stockholders, along with certain warrant holders, will have the opportunity to convert their holdings into common stock. The Company believes a more streamlined capitalization structure will strengthen shareholder alignment, improve marketability, and support its long-term strategic objectives. These actions reflect Creatd's continued focus on enhancing its public company profile and creating a capital structure better suited for future growth.

    About Creatd, Inc.

    Creatd, Inc. (OTCQB:CRTD) is a company focused on technology-enabled businesses, digital media properties, and intellectual property assets. Through its operating subsidiaries and strategic investments, the Company develops and supports opportunities for creators, entrepreneurs, and emerging growth initiatives.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Creatd undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

    Contact:

    ir@creatd.com



    Primary Logo

    Get the next $CRTD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRTD
    $VTAK

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $CRTD
    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    SEC Filings

    View All

    SEC Form S-1 filed by Catheter Precision Inc.

    S-1 - Catheter Precision, Inc. (0001716621) (Filer)

    6/22/26 4:20:25 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form S-1 filed by Creatd Inc.

    S-1 - Creatd, Inc. (0001357671) (Filer)

    6/22/26 11:44:40 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    6/8/26 6:16:04 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Creatd Files Form S-1, Reports First Quarter 2026 Results and Updates Annual Meeting Schedule

    First Quarter Results Filed: Creatd filed its Quarterly Report for the period ended March 31, 2026, reviewed by the Company's PCAOB-registered independent auditors, highlighting significant balance sheet developments following the disposition of Flyte.SEC Registration Progress: The Company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission as part of its initiative to re-establish SEC reporting status.Annual Meeting Update: Creatd has revised the record date for its annual shareholder meeting to Friday, June 26, 2026, and the meeting date to Monday, August 3, 2026. Shareholders of record as of June 26, 2026, will be entitled to vote at the meeting

    6/23/26 9:15:00 AM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open

    Partnership positions Flyte within elite professional sports ecosystem through leading talent agency GSE Worldwide Collaboration highlights growing demand for efficient regional travel solutions among professional athletes FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Flyte, the rapidly growing Regional Air Mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), today announced a partnership with sports and entertainment agency GSE Worldwide and PGA TOUR professional Emiliano Grillo that began this past weekend in the U.S. Open Championship. Grillo delivered an impressive performance at the 2026 U.S. Open, climbing as high as third place on the leaderboard during the champions

    6/22/26 4:15:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Volato Closes $2.2 Million PIPE Priced at $0.34 Per Share

    Strategic investors support Volato’s AI-driven aviation strategy and next phase of growth across software-enabled operating platforms Volato Group, Inc. (NYSE:SOAR) ("Volato" or the "Company") today announced the closing of a $2.2 million private investment in public equity ("PIPE") financing priced at $0.34 per share. The financing strengthens Volato’s balance sheet and provides additional capital flexibility as the Company advances its AI-focused strategy, including the application of its artificial intelligence technology, aviation operating experience, and software development capabilities to private aviation and other software-enabled markets. Volato is also evaluating acquisition,

    6/22/26 9:00:00 AM ET
    $SOAR
    $VTAK
    Transportation Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Financials

    Live finance-specific insights

    View All

    Creatd Finalizes 2025 Audit, Submits Amended Draft Registration Statement on Form S-1 to SEC, Ahead of Planned Uplisting and AI Acquisitions

    NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) today announced that it has finalized its audited financial statements for the fiscal year ended December 31, 2025. The completion of the 2025 audit represents a key milestone in the Company's ongoing efforts to strengthen its financial reporting framework and advance its capital markets strategy. For the fiscal year ended December 31, 2025, Creatd reported revenue of $3.2 million, compared with $1.5 million in 2024, an increase of $1.7 million approximately or 113%. The Company also reported stockholders' equity of $9 million at year-end 2025, compared with a stockholders' deficit of $10.4 million at year-end 2024, refl

    5/5/26 9:15:00 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Creatd, Inc. (OTCQB: CRTD) Announces Record Date and Annual Shareholder Meeting

    NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) ("The Company") is pleased to announce that the record date for its upcoming annual shareholder meeting is April 17, 2026. The virtual shareholder meeting is scheduled to take place on May 21, 2026. Shareholders of record as of the close of business on the record date will be entitled to notice of, and to vote at, the virtual annual meeting. Jeremy Frommer, CEO of Creatd, Inc., stated, "We are preparing to file our 2025 audited financials and complete the necessary steps to re-register with the SEC in the coming weeks. This marks the next phase of our uplisting process, following our achievement of trading above $4.00

    3/27/26 8:45:02 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    $CRTD
    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Creatd (CRTD) Announces OG Collection, Inc. Equity Realignment as Part of Broader Uplisting Strategy

    Board-approved OG Collection transactions expected to increase Creatd's ownership from approximately 20% to 51% Realignment follows the previously announced Vocal equity realignment and Flyte transaction Transaction further strengthens Creatd's balance sheet and uplisting strategy NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) today announced that its Board of Directors has approved a targeted equity realignment and repurchase initiative with respect to its subsidiary, OG Collection, Inc., designed to restore Creatd's majority ownership. The transaction represents the next step in the Company's broader corporate turnaround, SEC re-registration process, and planned

    5/28/26 9:15:00 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    CORRECTION: Creatd Announces Vocal Equity Realignment and Updates Annual Shareholder Meeting Dates

    NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Creatd Inc., please note that two dates given in the subhead, and repeated in the body text, were not correct. The annual shareholder meeting date will be June 5, not May 26 as previously stated. The virtual annual shareholder meeting date will be July 15, not June 25 as previously stated. The corrected release follows: Board-approved Vocal transactions expected to increase Creatd's ownership from approximately 20% to 51% Annual meeting record date updated to June 5, 2026; virtual shareholder meeting will be scheduled for July 15, 2026 Vocal 3.0 remains on track as Creatd advances its

    5/14/26 11:06:11 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    Creatd Announces Vocal Equity Realignment and Updates Annual Shareholder Meeting Dates

    Board-approved Vocal transactions expected to increase Creatd's ownership from approximately 20% to 51% Annual meeting record date updated to May 26, 2026; virtual shareholder meeting will be scheduled for June 25, 2026 Vocal 3.0 remains on track as Creatd advances its SEC re-registration, corporate reorganization, and planned uplisting strategy NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) ("Creatd" or the "Company") today announced two corporate updates related to its broader reorganization and planned uplisting strategy. First, both the Company's Board of Directors and the requisite shareholders of Vocal, Inc. ("Vocal") have approved a targeted equity realignme

    5/14/26 9:15:00 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    $CRTD
    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care